OUR PEOPLE: Innovation Board

The Innovation Board brings together the industrial and academic partners of the Consortium to determine the overarching challenges facing the pharmaceutical industry and predict future needs. It enables companies to collaborate on common research projects related to targets, technologies and therapeutic areas. The Consortium companies are in a position to fund collectively major projects of common interest. Its remit is to consider the future direction of therapeutic research and suggest innovative projects for collective company funding. Research projects selected by the Innovation Board are executed by a ‘task force’ of academic and company groups with appropriate expertise.

Dr Susan Galbraith

AstraZeneca
Vice President, Head of Oncology iMed, Innovative Medicines

Dr Sabina Cosulich

AstraZeneca
Director, Oncology Bioscience, Innovative Medicines

Dr John Lyons

Dr John Lyons

Astex
Senior Vice President of Translational Research

Dr Rab Prinjha

Dr Rab Prinjha

GlaxoSmithKline
Vice President, Head of Epigenetics Drug Performance Unit (DPU)

Dr Ron Newbold

Dr Ron Newbold

Pfizer
Vice President, External R&D Innovation

Dr Takeshi Shiota

Dr Takeshi Shiota

Shionogi
Senior Vice President, Pharmaceutical Research Division

Dr Kai Stoeber

Dr Kai Stoeber

Shionogi
Vice President,
Global Innovation

Dr Mathew Garnett

Dr Mathew Garnett

Sanger Institute
Group Leader, Translational Cancer Genomics

Prof Michael Wakelam

Prof Michael Wakelam

Babraham Institute
Director

Dr Simon Cook

Dr Simon Cook

Babraham Institute
Group Leader, Signalling Programme

Prof Tony Kouzarides

Prof Tony Kouzarides

University of Cambridge
Deputy Director, Gurdon Institute

Dr Richard Mason

Dr Richard Mason

Johnson & Johnson
Head of Johnson & Johnson Innovation, EMEA

Prof Greg Hannon

Royal Society Research Professor,
CRUK Cambridge Institute

Mark Morris

Mark Morris

Elysium
Vice President, Research and Development

Dr Kathryn Chapman

Executive Manager, Milner Therapeutics Institute
Ludovic Vallier

Prof Ludovic Vallier

Senior Group Leader, Laboratory for Regenerative Medicine, University of Cambridge